The in vitro activity of ciprofloxacin against 30 Bacteroides fragilis group, 30 Clostridium, and 30 Peptococcaceae strains was determined by the agar dilution method in two different culture media at three pH and in three inoculum densities. In Wilkins-Chalgren agar the MICs for 90% of the strains were 0.12 ,ug/ ml for B. fragilis, 0.5 ,ug/ml for Clostridium spp., and 2 ,g/ml for Peptococcaceae. The pH and medium composition affected the MICs ,ug/ml in Wilkins-Chalgren agar. Among the 30 Bacteroides strains, only five failed to produce beta-lactamase. Differences in susceptibility were not found between the betalactamase producers and nonproducers or among the different species of the B. fragilis group. Against Clostridium strains, the MICgo of ciprofloxacin was 0.5 pg/ml in WilkinsChalgren agar. Peptococcaceae were the most resistant group, showing a ciprofloxacin MIC90 of 2 p.g/ml.
, and beta-lactamase production was determined for all B. fragilis strains (7) . Four recommended reference strains were used for quality control (9 
4).
The MIC of ciprofloxacin against gram-positive facultatively anaerobic cocci (staphylococci and streptococci) has been reported to be in the range from 0.25 to 4 ,ug/ml (6) . We obtained a similar range of MIC for anaerobic gram-positive cocci (peptococci and peptostreptococci). The role of pH on ciprofloxacin activity against anaerobic bacteria is similar to that reported for facultatively anaerobic bacteria by other authors (1).
Our results of testing Bacteroides susceptibility to metronidazole agree with those reported by others (3, 10 Ciprofloxacin is more active than other nalidixic acid derivatives, such as norfloxacin (11) and ofloxacin (DL-8280) and pipemidic acid (8) , against anaerobic bacteria. It is well absorbed after oral administration to human volunteers and does not provoke significant side effects. After administration of 500 mg, the peak level obtained 1 h later is 1.58 pLg/ ml (A. Bauerfeind and G. Horl, Abstr. Eur. Congr. Clin. Microbiol. 1st, Bologna, abstr. no. 345, 1983) . It has been shown that this antimicrobial agent achieves higher levels in abscesses than in serum 30 min after intraperitoneal administration in mice (E. J. Perea, F. Martinez-Luengas, and M. C. Garcia-Iglesias, Abstr. Eur. Congr. Clin. Microbiol. 1st, Bologna, abstr. 352, 1983) . Based in the properties described above, it is reasonable to expect that this oxacina derivative would be therapeutically useful in systemic infections. Clinical studies on ciprofloxacin are in progress.
